Kalaris Therapeutics (KLRS) Cash from Investing Activities (2019 - 2026)

Kalaris Therapeutics' Cash from Investing Activities history runs 8 years deep, the most recent figure standing at -$50.3 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities changed N/A year-over-year to -$50.3 million; the TTM figure through Mar 2026 stood at -$10.4 million (changed N/A YoY), while the FY2025 annual figure was -$19.7 million, down 120.76% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at -$50.3 million, down from $15.0 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $41.7 million in Q1 2023, with the low at -$66.9 million in Q3 2023.
• The 5-year median for Cash from Investing Activities is $14.3 million (2022), against an average of $1.2 million.
• The sharpest annual moves came in 2022 and 2023: Cash from Investing Activities tumbled 184.81% in 2022, then jumped 8011.06% in 2023.
• Kalaris Therapeutics' Cash from Investing Activities stood at $13.5 million in 2022, then soared by 86.29% to $25.2 million in 2023, then sank by 80.17% to $5.0 million in 2024, then jumped by 199.66% to $15.0 million in 2025, then slumped by 436.05% to -$50.3 million in 2026.
• Business Quant data shows KLRS's Cash from Investing Activities at -$50.3 million in Q1 2026, $15.0 million in Q4 2025, and $5.0 million in Q4 2024.